Japan International Cooperation Agency (JICA) and the Government of Japan have been collaborating in the Pacific Programme for the Elimination of Lymphatic Filariasis (PacELF) for decades, achieving significant milestones. The Provision of Special Medical Equipment for Infection Control (Lymphatic Filariasis) Project, 2000- 2016, provided fourteen Pacific countries with Diethylcarbamazine Citrate (DEC), one of the drugs used in mass medication for Lymphatic Filariasis control, and test kits. In 2018- 2023, the Project for Elimination of Lymphatic Filariasis in the Pacific Region (Phase One) implemented Mass Drug Administration (MDA) and Transmission Assessment Survey (TAS) in each country and strengthened their capacities for six Pacific countries. In April 2023, The Lymphatic Filariasis Elimination Project Phase Two commenced as a continuation of Phase One. The project is working to strengthen the implementation capacity of MDAs and TAS/IDA impact studies (IIS) in seven targeted provinces in Papua New Guinea (PNG). The representatives from the target provinces and stakeholders have been invited to attend the project’s second Joint Coordinating Committee (JCC) meeting, which is scheduled to take place on Thursday the 28th of August 2025 at the National Department of Health in Waigani, Port Moresby. The meeting will provide an overview and discuss progress, the status of Lymphatic Filariasis measures in each province, and future plans.